Pacific Biosciences of California, Inc. (PACB) Stock

Pacific Biosciences of California, Inc., headquartered in Menlo Park, California, specializes in the design, development, and manufacturing of advanced sequencing systems tailored to unravel genetically complex challenges. Established in 2000 and originally known as Nanofluidics, Inc., the company rebranded as Pacific Biosciences in 2005 to reflect its expanded focus on cutting-edge biotechnology.

At the core of Pacific Biosciences' offerings are its PacBio Systems, which enable the execution, monitoring, and analysis of biochemical sequencing reactions with unparalleled precision. These systems are complemented by a range of consumable products, including the innovative single molecule real-time (SMRT) cells, essential for high-quality sequencing results. The company also provides diverse reagent kits tailored to specific sequencing workflows, such as template preparation kits that convert DNA into SMRTbell double-stranded DNA library formats, featuring molecular biology essentials like ligase, buffers, and exonucleases.

Pacific Biosciences serves a broad spectrum of customers across various sectors, including research institutions, commercial laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, academic institutions, pharmaceutical companies, and agricultural enterprises. Leveraging a direct sales force in North America and Europe, alongside strategic distribution partnerships in Asia, the Middle East, Africa, and Latin America, the company ensures global accessibility to its innovative sequencing solutions.

In pursuit of continuous innovation and market expansion, Pacific Biosciences collaborates actively with industry leaders. Notably, the company has forged a significant development and commercialization agreement with Invitae Corporation, underscoring its commitment to advancing genetic research and clinical applications worldwide. With a steadfast dedication to advancing biotechnology frontiers, Pacific Biosciences remains at the forefront of genomic sequencing technology, driving impactful advancements in scientific research and clinical diagnostics.